Reeta Rao Elected a Fellow of the American Academy of Microbiology

Rao and her research team use biochemical, molecular-genetic, and genomic tools to study strategies the fungal pathogens use to infect their hosts, identify how the pathogens interact with the host’s immune system, and explore how fungal infections are transmitted in the clinic. They also use high-throughput screening, a drug-discovery process used in the pharmaceutical industry to quickly test the biological or biochemical activity of a large number of compounds, to search for new therapeutics for fungal diseases, which are notoriously difficult to treat.

Along with her appointment at WPI, Rao is a visiting scientist at the Broad Institute of MIT and Harvard and a member of the Institute for Drug Resistance at the University of Massachusetts Medical School. She is a member of the American Association for the Advancement of Science, the National Association of Inventors, the Genetic Society of America, the Medical Mycology Society of the Americas, and the Indus Entrepreneurs, in addition to the American Society for Microbiology. She is also an associate editor of the open access journal PLOS ONE.

Before joining WPI in 2004, she was a postdoctoral researchers at the Whitehead Institute, supported by a National Institutes of Health (NIH) Ruth L. Kirschstein postdoctoral fellowship. She earned a BS in pharmacy at Birla Institute of Science and Technology in Pilani, India, an MS in bioscience and biotechnology and an MS in environmental sciences at Drexel University, and a PhD in biochemistry and molecular biology at Pennsylvania State University Medical College.

Her research, which has been supported by the NIH-funded Genomic Center for Infectious Diseases, the Massachusetts Clean Energy Council, Immunexcite Inc., and Irving A. Backman & Associates, among other organizations, has resulted in more than 20 peer-reviewed journal articles and invited review articles. Two of her papers have been featured by the Faculty of 1000 (F1000) publishing service (one was rated a “must read”), and a 2015 paper in the open-access journal eLife, “The evolution of drug resistance in clinical isolates of Candida albicans,” was accompanied by an "Insight" article by two researchers from École Polytechnique Fédérale in Lausanne, Switzerland, who commented on the importance of the study.